M&A Deal Summary |
|
---|---|
Date | 2021-02-24 |
Target | PRA Health Sciences |
Sector | Life Science |
Buyer(s) | ICON |
Deal Type | Add-on Acquisition |
Deal Value | 12.0B USD |
Advisor(s) | UBS Investment Bank (Financial) Paul, Weiss, Rifkind, Wharton & Garrison (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1990 |
Sector | Life Science |
Employees | 41,100 |
Revenue | 8.1B USD (2023) |
ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. ICON was founded in 1990 and is based in Dublin, Ireland.
DEAL STATS | # |
---|---|
Overall | 29 of 29 |
Sector (Life Science) | 16 of 16 |
Type (Add-on Acquisition) | 25 of 25 |
State (North Carolina) | 2 of 2 |
Country (United States) | 18 of 18 |
Year (2021) | 1 of 1 |
Size (of disclosed) | 1 of 9 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2020-02-19 |
MedPass International
Paris, France MedPass International is a European medical device CRO and consultancy. MedPass International is based in Paris, France. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2022-03-01 |
ICON - ADDPLAN Software
Dublin, Ireland ICON's ADDPLAN Software is a stand-alone software used to design, simulate, and analyze innovative adaptive clinical trials with functionality for all phases of clinical development. |
Sell | - |